Few taking advantage of quality ratings, price comparisons

Despite the focus on patient engagement, price transparency and provider quality ratings, few individuals are using quality and pricing data on physicians and hospitals to make their healthcare choices, according to a Kaiser Family Foundation poll.

The poll surveyed 1,506 adults from April 9 to April 14 and found that about two-thirds of respondents reported difficulties finding information on hospitals' and physicians' exact prices for treatments or procedures. Only about 20 percent of respondents reported seeing price or quality data about doctors, hospitals or insurers.

Less than 9 percent of respondents said they used pricing data when making decisions on health plans and only 6 percent of respondents said they used quality data when making a decision about a doctor, hospital or insurer. Three percent of respondents reported using pricing information when making decisions about physicians.

Less than half (47 percent) of insured respondents under age 65 said they would be able to immediately pay an unanticipated medical bill of $500 in full, while others said they would have to borrow money, pay in installments, use a credit card or not pay at all.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.